Aditi Shastri, MBBS

home / authors / aditi-shastri-mbbs

Articles

Saulius Girnius, MD;Jamie Koprivnikar, MD;Aditi Shastri, MBBS;Brittany Ragon, MD;Jamile Shammo, MD, FASCP, FACP;Michael Haddadin, MBBS;Kiran Naqvi, MD

December 19th 2025

FACE-OFF: Low-Risk MDS ASH 2025

Oral Hypomethylating Agents: Compliance, Real-World Data, and Expanding Use

Amer Zeidan, MBBS ;Ralph V. Boccia, MD, FACP ;Salman Fazal, MD ;Susan Granato, CRNP ;Aditi Shastri, MBBS

December 19th 2025

Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes in cancer treatment.

Introduction and Phase 3 COMMANDS Trial

Saulius Girnius, MD;Jamie Koprivnikar, MD;Aditi Shastri, MBBS;Brittany Ragon, MD;Jamile Shammo, MD, FASCP, FACP;Michael Haddadin, MBBS;Kiran Naqvi, MD

December 19th 2025

FACE-OFF: Low-Risk MDS ASH 2025

Long-Term Data on Oral Hypomethylating Agents

Amer Zeidan, MBBS ;Ralph V. Boccia, MD, FACP ;Salman Fazal, MD ;Susan Granato, CRNP ;Aditi Shastri, MBBS

December 19th 2025

Explore the latest advancements in oral hypomethylating agents for MDS and CMML, emphasizing their efficacy, patient convenience, and treatment strategies.